Literature DB >> 18448133

[Central nervous system neuromodulation for the treatment of epilepsy].

F Velasco1, A L Velasco, M Velasco, J D Carrillo-Ruiz, G Castro, D Trejo, J M Núñez.   

Abstract

We present here a review of the work on neuromodulation - defined as application of an inhibitory or excitatory current - on intracranial structures for the treatment of drug-resistant epilepsy. Near 250 patients were treated using a neuromodulation technique of the cerebellum (paravermian cortex), the CM-pf nucleus of the thalamus, the hippocampus, epileptogenic foci, and anterior ventral nucleus of the thalamus, with a one- to 15-year follow-up. Four contact strips were used for cerebellar and functional region neuromodulation, and DBS-type depth electrodes were stereotactically implanted for CM-pf and anterior nuclei of the thalamus and hippocampal neuromodulation. Electric stimulation was cyclic in almost all trials, using low frequency (10-40 Hz) for excitation and high frequency (60-185 Hz) for inhibition. Seizure frequency reduction was variable, depending on the neuromodulation site and patient selection, although seizure duration decreased in most patients. Cerebellar neuromodulation was followed by a 78% reduction in tonic and tonic-clonic seizures, CM-pf neuromodulation by an 83% reduction in tonic-clonic seizures and atypical absence of Lennox-Gastaut syndrome, with a 17.2% seizure-free and drug-free patient rate. Hippocampal neuromodulation was followed by a 73% reduction in partial complex seizures, with a 33% seizure-free patient rate. Anterior ventral nucleus of the thalamus was followed by a 63% reduction in tonic-clonic, tonic and atonic seizures. Several prognostic factors were identified in order to improve future results. There was no mortality and morbidity was limited to skin erosion at the neurostimulator site. Seizure reduction was associated with improved neuropsychological performance and better quality of life. Neuromodulation is safe and effective for the treatment of epileptic seizures of various origins. Several targets may be associated in a single patient, especially when bilateral hippocampal seizure foci are present.

Entities:  

Mesh:

Year:  2008        PMID: 18448133     DOI: 10.1016/j.neuchi.2008.02.034

Source DB:  PubMed          Journal:  Neurochirurgie        ISSN: 0028-3770            Impact factor:   1.553


  3 in total

1.  Epilepsy and Neuromodulation-Randomized Controlled Trials.

Authors:  Churl-Su Kwon; Valeria Ripa; Omar Al-Awar; Fedor Panov; Saadi Ghatan; Nathalie Jetté
Journal:  Brain Sci       Date:  2018-04-18

2.  Treatment of mesial temporal lobe epilepsy with amygdalohippocampal stimulation: A case series and review of the literature.

Authors:  Bao Min; Luan Guoming; Zhou Jian
Journal:  Exp Ther Med       Date:  2013-02-20       Impact factor: 2.447

3.  Dystrophin Distribution and Expression in Human and Experimental Temporal Lobe Epilepsy.

Authors:  Ruben G F Hendriksen; Sandra Schipper; Govert Hoogland; Olaf E M G Schijns; Jim T A Dings; Marlien W Aalbers; Johan S H Vles
Journal:  Front Cell Neurosci       Date:  2016-07-08       Impact factor: 5.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.